Source comparison
Tesamorelin + Ipamorelin Blend Benefits: Full Comparison
The tesamorelin + ipamorelin blend is often compared to other GH secretagogue combinations and to recombinant human growth hormone itself. The table below maps the key differentiators. Mechanism GHRH receptor + ghrelin receptor agonism (dual pathway) GHRH rece
This comparison does not assign a generated winner or score.
- The tesamorelin + ipamorelin blend is often compared to other GH secretagogue combinations and to recombinant human growth hormone itself. The table below maps the key differentiators.
- Mechanism
- GHRH receptor + ghrelin receptor agonism (dual pathway)
- GHRH receptor + ghrelin receptor (extended half-life)
- Direct exogenous GH replacement
- GHRH receptor agonism only
- Dual-pathway blends produce higher GH pulses without cortisol/prolactin elevation; tesamorelin + ipamorelin is the most selective combination
- Visceral Fat Reduction
- 15.2% VAT reduction at 26 weeks (clinical data)
- Comparable but less clinical validation
- 10–12% VAT reduction (supraphysiological dose required)
- 15.2% VAT reduction (same as blend at equivalent tesamorelin dose)
- Tesamorelin is the only peptide with FDA approval for lipodystrophy; ipamorelin adds GH amplitude without additional VAT-specific benefit
- Cortisol/Prolactin Elevation
- None (ipamorelin is selective; tesamorelin does not activate ACTH pathways)
- None with ipamorelin; CJC-1295 alone is neutral
- Variable. RhGH can elevate cortisol at high doses
- None
- Hormonal side-effect profile is cleanest with tesamorelin + ipamorelin vs older secretagogues (GHRP-2, GHRP-6)
- Insulin Sensitivity
- Improves over 26 weeks (HOMA-IR reduction) despite transient GH-induced glucose elevation
- Likely similar but undocumented in RCTs
- Worsens with chronic supraphysiological use (GH antagonizes insulin)
- Improves (same as blend)
- Pulsatile GH release improves insulin sensitivity long-term; continuous rhGH does the opposite
- Half-Life
- Tesamorelin 26–38 min; ipamorelin ~2 hours
- CJC-1295 (DAC) 6–8 days; ipamorelin ~2 hours
- rhGH ~2–3 hours (suppresses endogenous production)
- 26–38 minutes
- Short half-life peptides require daily dosing but preserve natural pulsatility; extended half-life (CJC-DAC) risks non-physiological GH patterns
- Dosing Frequency
- Once daily (evening preferred)
- Once daily or 2–3× weekly (CJC-DAC allows less frequent dosing)
- Daily injection (sometimes twice daily)
- Once daily
- Tesamorelin + ipamorelin requires daily administration but avoids the receptor desensitization risk of longer-acting analogs
- Cost (Research Use)
- Moderate (two peptides but lower per-dose cost than rhGH)
- Moderate (CJC-1295 DAC is more expensive than non-DAC forms)
- High (rhGH is 3–5× more expensive per equivalent GH elevation)
- Low (single peptide)
- Blend offers best cost-to-outcome ratio for VAT reduction and body recomposition studies